enoxaparin

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) gained more than 3 percent after the company agreed to license its developmental blood-thinning drug to a unit of Bayer AG (OTC: BAYRY). Carlsbad, California-based Isis changed hands recently at $60.35, up 3.6 percent. Under the license, Isis expects an...